OpGen (NASDAQ:OPGN) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research report released on Saturday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Up 42.3 %

Shares of NASDAQ OPGN opened at $0.75 on Friday. The firm’s fifty day moving average is $1.33 and its 200 day moving average is $1.95. OpGen has a 52 week low of $0.53 and a 52 week high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.